Loading chart data...
Viatris shares are trading higher in after-hours activity following a regular session that saw the stock finish roughly flat. While there have been no specific company announcements released since the market closed today, the move follows a period of positive sentiment surrounding the company's recent FDA approval for the Gwyn Lo contraceptive patch and successful Phase 3 study results for its VR-205 treatment. The stock is currently showing modest gains as it continues to navigate near its 50-day moving average, moving in a similar direction to broader industry peers like Pfizer.
That explains the day. Whether VTRS is a business worth owning is a longer question. Koyfin has the ten-year financials, margin history and valuation to answer it — 20% off for WhyTheMove readers.
No significant catalyst events detected.
VTRS moved for a reason you can read above. What the company earns, owns and guides to is a separate record. Koyfin is where the question moves from today's move to the business behind it — analyst estimates, filings and earnings transcripts.
Research VTRS in Koyfin →7-day full-access trial · 20% off paid plans